Advertisement

Topics

ASCO Panel Sees Greater Utility for Bone-Modifying Agents in Myeloma

15:22 EDT 17 May 2018 | OncLive

In updated guidelines exploring the role of bone-modifying agents, ASCO has recommended expanding the use of bisphosphonates to include all patients being treated for active multiple myeloma

Original Article: ASCO Panel Sees Greater Utility for Bone-Modifying Agents in Myeloma

NEXT ARTICLE

More From BioPortfolio on "ASCO Panel Sees Greater Utility for Bone-Modifying Agents in Myeloma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...